📰 4 sources covering this story

GLP-1 drugs are driving higher sales for Eli Lilly and Novo Nordisk

First covered 8 hrs ago · latest take 15 mins ago. Compare how each outlet is covering it — and rate the sources you trust.

Global News15 mins ago

Sales of Mounjaro, Eli Lilly’s diabetes drug, rose 91 per cent in the second quarter of the year to US$9.94 billion, well above analysts' expectations.

Trust?Read on Global News ↗

Reuters1 hrs ago

Lilly beats estimates on resilient demand for injectable GLP-1 drugs, widens gap with Novo

Lilly beats estimates on resilient demand for injectable GLP-1 drugs, widens gap with Novo Reuters

Trust?Read on Reuters ↗

MarketWatch2 hrs ago

How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

The Danish company developed the most lucrative new drug the world had ever seen. Then America’s Eli Lilly outmaneuvered it and took control of the diet-drug market.

Trust?Read on MarketWatch ↗

CNBC🏁 first to report8 hrs ago

Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge

Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from a previous guidance of $82 billion and $85 billion.

Trust?Read on CNBC ↗